Scott Michael Palmer, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Vice-Chair for Research in the Department of Medicine
Professor in Immunology
Professor in Population Health Sciences
Core Faculty in Innovation & Entrepreneurship
Campus mail 2085 Msrb2 2 Genome Ct, Durham, NC 27710
Phone (919) 684-0245
Email address

Dr. Palmer leads a successful program of clinical, basic and translational research in transplantation and advanced lung diseases. He currently directs the pulmonary research program at the Duke Clinical Research Institute (DCRI) and serves as Vice Chair for Research in the Department of Medicine.

Dr. Palmer has over 150 peer reviewed publications, received numerous awards, including election into the American Society for Clinical Investigation (ASCI) in 2012, chaired many sessions at national and international meetings, serves regularly on NIH study sections, and is on the editorial board of many prominent journals. He is also Associate Director of the Clinical Research Training Program at Duke and has personally mentored over 40 pre-and post-doctoral trainees, many of whom are now engaged in their own successful research careers.

His scientific accomplishments include the first human studies to demonstrate the importance of innate immunity in transplant rejection and completion of a prospective multicenter study that improved CMV prevention after lung transplantation.

Current basic projects in the lab are studying the role of the matrix in the activation of innate immunity in pulmonary transplant rejection, and epithelial injury and repair in the development of toxin induced bronchiolitis obliterans. Translational and human projects are studying predictors of lung transplant survival in the UNOS database, immune monitoring to predict CMV infection and acute rejection after lung transplantation, and the use of novel inhaled antibiotics in lung transplantation. The lab is also using cutting edge whole exome genetic sequencing to identify genetic predictors of transplant rejection.

Dr. Palmer also leads trials coordinated through the DCRI that study the natural history and investigate new treatments for idiopathic pulmonary fibrosis (IPF), chronic lung transplant rejection, and posttransplant cytomegalovirus infection.

Education and Training

  • Fellow, Pulmonary Medicine, Medicine, Duke University, 1996 - 1999
  • Medical Resident, Medicine, Duke University, 1993 - 1996
  • M.H.S., Duke University, 2000
  • M.D., Duke University, 1993


Podolanczuk, Anna J., Elizabeth C. Oelsner, R Graham Barr, Eric A. Hoffman, Hilary F. Armstrong, John H. M. Austin, Robert C. Basner, et al. “High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study..” The European Respiratory Journal 48, no. 5 (November 2016): 1442–52.

Full Text

Hubbs, Ann F., Kara L. Fluharty, Rebekah J. Edwards, Jamie L. Barnabei, John T. Grantham, Scott M. Palmer, Francine Kelly, et al. “Accumulation of Ubiquitin and Sequestosome-1 Implicate Protein Damage in Diacetyl-Induced Cytotoxicity..” The American Journal of Pathology 186, no. 11 (November 2016): 2887–2908.

Full Text

Ali, H. A., S. Palmer, and O. Manuel. “Special considerations for long term survivors after solid organ transplantation..” In Transplant Infections Fourth Edition. Springer, 2016.


DerHovanessian, Ariss, Jamie L. Todd, Alice Zhang, Ning Li, Aradhna Mayalall, C Ashley Finlen Copeland, Michael Shino, et al. “Validation and Refinement of Chronic Lung Allograft Dysfunction Phenotypes in Bilateral and Single Lung Recipients..” Annals of the American Thoracic Society 13, no. 5 (May 2016): 627–35.

Full Text

Cantu, E., J. Diamond, J. Nellen, B. Beduhn, Y. Suzuki, C. Borders, J. Lasky, et al. “Redefining Primary Graft Dysfunction after Lung Transplantation.” In The Journal of Heart and Lung Transplantation, 35:S89–S89. Elsevier BV, 2016.

Full Text

Smith, P. J., J. Blumenthal, J. Mathew, B. M. Hoffman, S. Rivelli, M. Durheim, and S. M. Palmer. “Depression, Quality of Life, and Mortality Early Following Lung Transplantation.” In The Journal of Heart and Lung Transplantation, 35:S227–28. Elsevier BV, 2016.

Full Text

Todd, J. L., C. A. Finlen Copeland, M. Neely, and S. M. Palmer. “FVC and FEV1 Decline in Chronic Lung Allograft Dysfunction (CLAD) Phenotypes.” In The Journal of Heart and Lung Transplantation, 35:S223–24. Elsevier BV, 2016.

Full Text

Setten, J. van, N. de Jonge, M. V. Holmes, K. K. Khush, N. K. Sweitzer, P. Garcia-Pavia, J. W. Rossano, et al. “The Role of Loss-of-Function Mutations on Death and Development of Rejection in HTX/LTX Patients.” In The Journal of Heart and Lung Transplantation, 35:S191–S191. Elsevier BV, 2016.

Full Text

Diamond, Joshua M., Mary K. Porteous, L Jackson Roberts, Nancy Wickersham, Melanie Rushefski, Steven M. Kawut, Rupal J. Shah, et al. “The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia..” The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 35, no. 4 (April 2016): 500–507.

Full Text

Durheim, M. T., D. M. Wojdyla, C. L. Green, S. Keshavjee, K. McCurry, A. O. Lidor, R. D. Davis, S. M. Palmer, and J. L. Todd. “Evaluation of an FVC-Based Definition of Restrictive Chronic Lung Allograft Dysfunction (CLAD) in a Multi-Center Cohort.” In The Journal of Heart and Lung Transplantation, 35:S117–18. Elsevier BV, 2016.

Full Text